Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding the Finalization of the Terms and Other Details of Stock Acquisition Rights (Stock Options) to Be Issued to Employees of the Company

The payment amount and other previously undetermined terms of the 69th series of stock acquisition rights for employees, approved on 24 March 2026, have been finalized. A total of 30,827 stock acquisition rights will be granted to 77 employees, covering 770,675 shares.

Worth reading
31Immaterial
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2400
¥ per stock acquisition right
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Stock acquisition rights (stock options) to be issued to the Company's employees

Who receives how much770,675Shares

770,675 shares of the Company's common stock

77 employees of the Company, 30,827 stock acquisition rights

The lower thin line represents the existing number of shares to which these shares will be added.

¥2,400 per stock acquisition right and ¥96 per share
Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total number issued: 30,827; number of outstanding unexercised rights: Not disclosed
Categories and Number of Persons Covered
77 employees of the Company, 30,827 stock acquisition rights
Details of issuance or disposal
ItemDetails
Type of issuance or disposalStock acquisition rights (stock options) to be issued to the Company's employees
Number of shares to be issued or disposed of770,675 shares of the Company's common stock
Issue price and disposal price¥2,400 per stock acquisition right and ¥96 per share
Intended allottee77 employees of the Company, 30,827 stock acquisition rights
Number of Stock Acquisition RightsTotal number issued: 30,827; number of outstanding unexercised rights: Not disclosed
Categories and Number of Persons Covered77 employees of the Company, 30,827 stock acquisition rights
Items this document does not state (22)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The previously undetermined terms of the employee stock options approved at the Board of Directors meeting held on 24 March 2026 have been finalized. The Company also explains that the issuance of these stock acquisition rights does not constitute a favorable issuance.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Finalization of the Terms and Other Details of Stock Acquisition Rights (Stock Options) to Be Issued to Employees of the Company | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori